PPARα agonists such as fibrates are widely prescribed for the treatment of dyslipidemias as lipid‐lowering drugs in the clinic.[58] In our study, wogonin improved the lipid profile, which may be dependent on its stimulation of the PPARα signaling pathway. Here, PPARA is linked to metabolic syndrome.